<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="168137">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01869699</url>
  </required_header>
  <id_info>
    <org_study_id>UCSF-ICUFever</org_study_id>
    <nct_id>NCT01869699</nct_id>
  </id_info>
  <brief_title>Effects of Intravenous Acetaminophen on Body Temperature and Hemodynamic Responses in Febrile Critically Ill Adults</brief_title>
  <acronym>ICUFeverAPAP</acronym>
  <official_title>Effects of Intravenous Acetaminophen on Body Temperature and Hemodynamic Responses in Febrile Critically Ill Adults: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effects of intravenous acetaminophen to placebo
      on body temperature and hemodynamic (heart rate and blood pressure) responses in febrile
      critically ill adult patients.

      There are limited data to explain the variable and unpredictable antipyretic and hemodynamic
      response to acetaminophen in febrile ICU patients.  The complex pathophysiology of
      critically ill patients, co-morbid conditions, the effect of multiple pharmacologic and
      non-pharmacologic care interventions, and/or the potential interferences with absorption of
      enteral or rectal formulations may be related to variations in the antipyretic response to
      acetaminophen.  It is necessary for clinicians to have a better understanding of the therapy
      response and potential adverse effects of this commonly administered medication, especially
      the recently available IV formulation, in critically ill patients.  Further research of the
      antipyretic response to acetaminophen in critically ill patients is warranted to inform
      evidence-based practice guidelines for fever management. Further randomized,
      placebo-controlled studies of hemodynamic responses to IV acetaminophen are also warranted.

      Primary Hypothesis:

      There is a significant reduction in time-weighted average core body temperature over 4 hours
      after administration of IV acetaminophen compared to placebo in febrile critically ill
      patients.

      Secondary Hypotheses:

        1. There is a significant reduction in time-weighted average heart rate over 4 hours after
           administration of IV acetaminophen compared to placebo in febrile critically ill
           patients.

        2. There is a significant reduction in time-weighted mean arterial pressure over 4 hours
           after administration of IV acetaminophen compared to placebo in febrile critically ill
           patients.

      Adult patients with fever (≥ 38.3ºCentigrade/101ºFarenheit) in the intensive care unit will
      be screened for eligibility and enrolled after informed consent. Patients will be randomized
      to receive IV acetaminophen 1 gram or normal saline 100 mLs. Body temperature, heart rate,
      and blood pressure will be measured at baseline and during the 4 hours post study drug
      administration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adult patients with fever (≥ 38.3ºCentigrade (C)/101ºFarenheit(F)) in the intensive care
      unit will be screened for eligibility and approached for informed consent.  Enrolled
      patients will be stratified based on the leading etiology of their fever: either neurologic
      injury or infection and then randomized to receive IV acetaminophen 1 gram or normal saline
      100 milliliters (mLs). Core body temperature will be measured using a zero-heat flow
      thermometry system (non-invasive, small disk on forehead). Patients will be monitored and
      data collected during the 4-hour post study drug administration period.  A rescue protocol
      will be implemented if the temperature reaches ≥ 40 ºC during the study period and includes
      notification of primary team provider by the nurse and the pharmacist will contact them to
      inform the provider of study group (acetaminophen or placebo). The provider can decide
      whether to order antipyretic medication or physical cooling interventions at that time.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>core body temperature</measure>
    <time_frame>4 hours post study drug administration</time_frame>
    <safety_issue>No</safety_issue>
    <description>time-weighted average core body temperature over 4 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>heart rate</measure>
    <time_frame>4 hours post study drug administration</time_frame>
    <safety_issue>No</safety_issue>
    <description>time-weighted average heart rate over 4 hours</description>
  </secondary_outcome>
  <other_outcome>
    <measure>blood pressure</measure>
    <time_frame>4 hours post study drug administration</time_frame>
    <safety_issue>No</safety_issue>
    <description>time-weighted average blood pressure over 4 hours</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Fever</condition>
  <condition>Critical Illness</condition>
  <arm_group>
    <arm_group_label>Normal saline placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline 100 mLs intravenous, administered over 15 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acetaminophen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acetaminophen 1 gram/100 mLs intravenous, single dose administered over 15 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen</intervention_name>
    <description>acetaminophen 1 gram/100mLs intravenously administered over 15 minutes</description>
    <arm_group_label>Acetaminophen</arm_group_label>
    <other_name>Ofirmev</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal saline placebo  Normal saline 100 mLs intravenous, administered over 15 minutes</description>
    <arm_group_label>Normal saline placebo</arm_group_label>
    <other_name>NS</other_name>
    <other_name>0.9% sodium chloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age and older

          -  Patient in an intensive care unit

          -  Weight greater or equal to 50 kgs

          -  Fever: core body temperature greater than or equal to 38.3 degrees Celsius

          -  Clinically stable: no active resuscitation with fluids, blood products, or  dose
             increases of vasoactive medications within 1 hour of study drug administration

        Exclusion Criteria:

          -  Acetaminophen hypersensitivity

          -  Acute liver failure or acute liver injury

          -  Heat stroke, malignant hyperthermia, neuroleptic malignant syndrome

          -  Therapeutic cooling, physical cooling, extracorporeal blood circuit therapies

          -  Administration of acetaminophen-containing medications, non-steroidal
             anti-inflammatory drugs, or aspirin greater than 81 mg within specified times per
             drug prior to fever presentation
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathleen A. Puntillo, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kathleen A Puntillo, PhD</last_name>
    <phone>415-476-1844</phone>
    <email>kathleen.puntillo@nursing.ucsf.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hildegarde Schell-Chaple, PhD(c)</last_name>
    <phone>415-353-1039</phone>
    <email>hildy.schell@ucsfmedctr.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California, San Francisco Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hildegarde Schell-Chaple, MS</last_name>
      <phone>415-353-1039</phone>
      <email>hildy.schell@ucsfmedctr.org</email>
    </contact>
    <investigator>
      <last_name>Hildegarde Schell-Chaple, PhD(c)</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kathleen Puntillo, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCSF Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hildegarde Schell-Chaple, PhD(c)</last_name>
      <phone>415-353-1039</phone>
      <email>hildy.schell@ucsfmedctr.org</email>
    </contact>
    <contact_backup>
      <last_name>Kathleen Puntillo, PhD</last_name>
      <phone>415-476-1844</phone>
      <email>kathleen.puntillo@nursing.ucsf.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Kathleen Puntillo, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hildegarde Schell-Chaple, PhD(c)</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Matthay, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Sessler, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Laupland KB, Zahar JR, Adrie C, Schwebel C, Goldgran-Toledano D, Azoulay E, Garrouste-Orgeas M, Cohen Y, Jamali S, Souweine B, Darmon M, Timsit JF. Determinants of temperature abnormalities and influence on outcome of critical illness. Crit Care Med. 2012 Jan;40(1):145-51. doi: 10.1097/CCM.0b013e31822f061d.</citation>
    <PMID>21926588</PMID>
  </reference>
  <reference>
    <citation>Lee BH, Inui D, Suh GY, Kim JY, Kwon JY, Park J, Tada K, Tanaka K, Ietsugu K, Uehara K, Dote K, Tajimi K, Morita K, Matsuo K, Hoshino K, Hosokawa K, Lee KH, Lee KM, Takatori M, Nishimura M, Sanui M, Ito M, Egi M, Honda N, Okayama N, Shime N, Tsuruta R, Nogami S, Yoon SH, Fujitani S, Koh SO, Takeda S, Saito S, Hong SJ, Yamamoto T, Yokoyama T, Yamaguchi T, Nishiyama T, Igarashi T, Kakihana Y, Koh Y; Fever and Antipyretic in Critically ill patients Evaluation (FACE) Study Group. Association of body temperature and antipyretic treatments with mortality of critically ill patients with and without sepsis: multi-centered prospective observational study. Crit Care. 2012 Feb 28;16(1):R33. doi: 10.1186/cc11211.</citation>
    <PMID>22373120</PMID>
  </reference>
  <reference>
    <citation>Laupland KB, Shahpori R, Kirkpatrick AW, Ross T, Gregson DB, Stelfox HT. Occurrence and outcome of fever in critically ill adults. Crit Care Med. 2008 May;36(5):1531-5. doi: 10.1097/CCM.0b013e318170efd3.</citation>
    <PMID>18434882</PMID>
  </reference>
  <reference>
    <citation>Circiumaru B, Baldock G, Cohen J. A prospective study of fever in the intensive care unit. Intensive Care Med. 1999 Jul;25(7):668-73.</citation>
    <PMID>10470569</PMID>
  </reference>
  <reference>
    <citation>Frankenfield DC, Smith JS Jr, Cooney RN, Blosser SA, Sarson GY. Relative association of fever and injury with hypermetabolism in critically ill patients. Injury. 1997 Nov-Dec;28(9-10):617-21.</citation>
    <PMID>9624339</PMID>
  </reference>
  <reference>
    <citation>Thompson HJ, Kagan SH. Clinical management of fever by nurses: doing what works. J Adv Nurs. 2011 Feb;67(2):359-70. doi: 10.1111/j.1365-2648.2010.05506.x. Epub 2010 Nov 2.</citation>
    <PMID>21044137</PMID>
  </reference>
  <reference>
    <citation>Niven DJ, Stelfox HT, Laupland KB. Antipyretic therapy in febrile critically ill adults: A systematic review and meta-analysis. J Crit Care. 2013 Jun;28(3):303-10. doi: 10.1016/j.jcrc.2012.09.009. Epub 2012 Nov 14.</citation>
    <PMID>23159136</PMID>
  </reference>
  <reference>
    <citation>de Maat MM, Tijssen TA, Brüggemann RJ, Ponssen HH. Paracetamol for intravenous use in medium--and intensive care patients: pharmacokinetics and tolerance. Eur J Clin Pharmacol. 2010 Jul;66(7):713-9. doi: 10.1007/s00228-010-0806-5. Epub 2010 Mar 19.</citation>
    <PMID>20300741</PMID>
  </reference>
  <reference>
    <citation>Kett DH, Breitmeyer JB, Ang R, Royal MA. A randomized study of the efficacy and safety of intravenous acetaminophen vs. intravenous placebo for the treatment of fever. Clin Pharmacol Ther. 2011 Jul;90(1):32-9. doi: 10.1038/clpt.2011.98. Epub 2011 May 4.</citation>
    <PMID>21544074</PMID>
  </reference>
  <reference>
    <citation>Mackenzie I, Forrest K, Thompson F, Marsh R. Effects of acetaminophen administration to patients in intensive care. Intensive Care Med. 2000 Sep;26(9):1408.</citation>
    <PMID>11089781</PMID>
  </reference>
  <reference>
    <citation>Boyle M, Hundy S, Torda TA. Paracetamol administration is associated with hypotension in the critically ill. Aust Crit Care. 1997 Dec;10(4):120-2.</citation>
    <PMID>9708071</PMID>
  </reference>
  <reference>
    <citation>Boyle M, Nicholson L, O'Brien M, Flynn GM, Collins DW, Walsh WR, Bihari D. Paracetamol induced skin blood flow and blood pressure changes in febrile intensive care patients: An observational study. Aust Crit Care. 2010 Nov;23(4):208-14. doi: 10.1016/j.aucc.2010.06.004. Epub 2010 Jul 22.</citation>
    <PMID>20655241</PMID>
  </reference>
  <reference>
    <citation>Hersch M, Raveh D, Izbicki G. Effect of intravenous propacetamol on blood pressure in febrile critically ill patients. Pharmacotherapy. 2008 Oct;28(10):1205-10. doi: 10.1592/phco.28.10.1205.</citation>
    <PMID>18823215</PMID>
  </reference>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 3, 2014</lastchanged_date>
  <firstreceived_date>May 31, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fever</keyword>
  <keyword>Acetaminophen</keyword>
  <keyword>Critical Care</keyword>
  <keyword>ICU</keyword>
  <keyword>Febrile</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Critical Illness</mesh_term>
    <mesh_term>Fever</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
